The immunogenicity and safety of three-component DTaP vaccine in Korean infants |
Kang, Jin Han
(Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kim, Jong Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Lee, Jung Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Lee, Soo Young (Department of Pediatrics, College of Medicine, The Catholic University of Korea) Hong, Young Jin (Department of Pediatrics, College of Medicine, Inha University) Kim, Chang Hwi (Department of Pediatrics, College of Medicine, Sooncheonhyang University) |
1 | Miller E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals 1999;27:79-86 DOI ScienceOn |
2 | Schmitt HJ, von Konig CHW, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41 DOI |
3 | Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al. A randomized double blind trial comparing a two-component acellular to a whole cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-12 DOI ScienceOn |
4 | Olin P, Ramussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial two component, three component, and five component acellular pertussis vaccine compared with whole cell pertussis vaccine. Lancet 1997; 350:1569-77 DOI ScienceOn |
5 | Edwards KM, Decker MD. Acellular pertussis vaccines for infants [editorial]. N Engl J Med 1996;334:391-2 DOI ScienceOn |
6 | Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors p.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998;66:670-5 |
7 | Liese JG, Stojanov S, Zink TH, Froeschle J, Klepadlo R, Kronwitter A, et al. Safety and immunogenicity of Biken acellualr pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J 2001;20:981-8 DOI ScienceOn |
8 | Hellwig SMM, van Oirschot HF, Hazenbos WI, van Spriel AB, Mooi FR, van De Winkel JGJ. Targeting to Fc gamma receptors, but not CR3(CD11b/CD18), increases clearance of Bordetella pertussis. J Infect Dis 2001;183:871-9 DOI ScienceOn |
9 | de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly accinated population of the Netherlands: observation on surveillance data. Emerg Infect Dis 2000;6:348-57 DOI ScienceOn |
10 | Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001;108(5);E81 |
11 | Bernstein HH, Rothstein EP, Pichichero ME, Green JL, Reisinger KS, Blatter MM, et al. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2,4 and 6 month old infants in the United States. Vaccine 1995;13:1631-5 DOI ScienceOn |
12 | Romanus V, Jonsell R, Bergquist S-O. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987;6:367-71 |
13 | Isacson J, Trollfors B, Taranger J, Zackrisson G, Laergard T. How common is whooping cough in a non-vaccinationg country? Pediatr Infect Dis J 1993;12:284-8 DOI ScienceOn |
14 | Christy C, Picheichero ME, Reed GF, Decker MD, Anderson EL, Rennels MB, et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole cell pertussis vaccines. Pediatrics 1995;96:584-7 |
15 | Pichichero ME, Green JL, Francis AB, Marsocci SM, Lynd AM, Litteer T. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in twomonth- old children. Pedatr Infect Dis J 1994;13:193-6 DOI ScienceOn |
16 | Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 2000;182:1402-8 |
17 | Zepp F, Knuf M, Harbermel P, Schimitt HJ, Rebsch C, Schmidtke P, et al. Pertussis specific cell mediated immunity in infants after vaccination ith a tri-component acellular pertussis vaccine. Infect Immun 1996;64:4078-84 |
18 | Ulmer JB, Liu MA. Ethical issues for vaccines and immunization. Nat Rev Immunol 2002;2:291-6 DOI ScienceOn |
19 | Decker MD, Edwards K, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines; adverse reactions. Pediatrics 1995; 96:557-66 |
20 | Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic responses. Pediatrics 1995;96:548-57 |
21 | Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999;67:3133-4 |
22 | Storsaeter J, Hallander H, Farrington CP, Olin P, Mollby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990;8:457-61 DOI ScienceOn |
23 | Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987;9:866-83 DOI |
24 | Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, et al. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991;78:885-9 |
25 | Ad Hoc group for the study of pertussis vaccines. Placebo- controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1988; 30:955-60 |
26 | Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. N Engl J Med 1996;334:341-8 DOI ScienceOn |
27 | Zepp F, Knuf M, Habermehl P, Schmitt HJ, Meyer C, Clemens R, et al. Cell-mediated immunity after pertussis vaccination and after natural infection. Dev Biol Stand 1997; 89:307-14. |
28 | Halsey NA, Peter G. New developments with pertussis vaccines. Clin Immunother 1995;96:970-1 |
29 | Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001;32:1691-7 DOI ScienceOn |
30 | Njamkepo E, Rimlinger F, Thiberge S, Guiso N, Thirty five years experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002;20:1290-4 DOI ScienceOn |
31 | Schmitt HJ, Schuind A, Knuf M, Zepp F, Beutel K, Wirsing von Konig CH, et al. Acellular pertussis vaccine: the rationale for an efficacy trial in Germany. J Infect Dis 1996;174 Suppl 3:S287-90 DOI |
32 | Liese JG, Meschievitz CK, Harzer E, Froeschle J, Hosbach P, Hoppe JE, et al. Efficacy of two component acellular pertussis vaccine in infants. Pediatr Infect Dis 1997;16: 1038-44 DOI ScienceOn |
33 | Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two component acellular, a five component acellular, and a whole cell pertussis vaccine. N Engl J Med 1996;334:349-55 DOI ScienceOn |
34 | Sato Y, Sato H. Developments of acellular pertussis vaccines. Biologicals 1999;27:61-9 DOI ScienceOn |
35 | Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001;7(3 Suppl)526S-528 DOI ScienceOn |
36 | Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000;105:e11 |
37 | Kanai K. Japan's experience in pertussis epidemiology and vaccination in the past thirty years. Jpn J Med Sci Biol 1980;33:107-43 DOI |
38 | Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Enguland JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis tetanus diphtheria vaccines. Pediatrics 2000;105:e12 DOI ScienceOn |
39 | Noble GR, Bernier RH, Esber EC, Hardegree MC, Hinman AR, Klein D, et al. Acellular and whole cell pertussis vaccines in Japan. Report of a visit by US scientist. JAMA 1987;257:1351-6 DOI |